Cynata Therapeutics Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CYP.AX research report →
Price Chart
About the company
Headquartered in Cremorne, Australia, Cynata Therapeutics Limited, established in 2003 and formerly known as Eco Quest Limited until its 2013 rebranding, specializes in the development and commercialization of its proprietary Cymerus mesenchymal stem cell technology for human therapeutic applications. Its most advanced therapeutic candidate, CYP-001, has successfully concluded Phase I clinical trials for graft versus host disease. The company's pipeline also includes CYP-004, currently in Phase III trials for osteoarthritis treatment, and CYP-006TK, an innovative polymer-coated silicon wound dressing designed for diabetic wounds.
- CEO
- Kilian Kelly
- IPO
- 2007
- HQ
- Cremorne, VIC, AU
Get TickerSpark's AI analysis on CYP.AX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.92M
- P/E
- -0.33
- PEG
- -0.01
- P/S
- -34.38
- P/B
- 0.83
- EV/EBITDA
- -0.03
- Div Yield
- 0.00%
- Gross Margin
- 253.27%
- Op Margin
- 16974.06%
- Net Margin
- 9887.90%
- ROE
- -179.37%
- ROIC
- -353.74%
Latest fiscal year · YoY change
- Revenue
- $1.89M-18.6%
- Gross Profit
- $1.89M-18.6%
- Op Income
- $-8,124,003
- Net Income
- $-9,390,586+3.6%
- EPS
- $-0.05+15.5%
- OCF Growth
- +12.5%
- FCF Growth
- +11.9%
- 52W High
- $0.43
- 52W Low
- $0.01
- 50D MA
- $0.03
- 200D MA
- $0.24
- Beta
- 1.10
- RSI (14)
- 24
- Avg Volume
- 3.25M
No earnings-call transcripts are available for CYP.AX yet.
- Free Float
- 80.9%
- Shares Outstanding
- 243.45M
- Float Shares
- 196.98M
Our CYP.AX coverage
Recent articles, reports, and earnings notes.
No research on CYP.AX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CYP.AX report →Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.